IO Case Study (IHC): AI-powered Biomarker Quantification Could Accelerate Trial Enrollment
Challenge: Manual PD-L1 IHC scoring has high variability, accuracy, and sensitivity issues and could misclassify patients, resulting in delays during trial enrollment.
Solution: AI-assisted scoring recategorized 18% of cases from the ‘treatment ineligible’ PD-L1 negative group to PD-L1 positive group (retrospective study)
Deep Learning-Based Evaluation of PD-L1 Immunohistochemistry-Stained Slides for Robust Tumor Proportion Scoring Enables Better Categorization of Non-Small-Cell Lung Cancer Cases.
